Tonghua Dongbao: the first patient enrolled in Phase I Clinical trial of Gout] Tonghua Dongbao announced that the company's wholly-owned subsidiary Dongbao Zixing has started the phase Ⅰ clinical trial and recently completed the first subject enrollment after receiving a notice of approval for the clinical trial of gout dual-target inhibitors (THDBH151 tablets) issued by the Drug Evaluation Center of the State Drug Administration.